Home / Business and Economy / L'Oreal Adapts to GLP-1 Impact on Beauty Sales
L'Oreal Adapts to GLP-1 Impact on Beauty Sales
23 Oct
Summary
- Weight loss drug side effects are impacting beauty sales.
- L'Oreal designs products to combat skin sagging from rapid weight loss.
- GLP-1 drug popularity affects L'Oreal's skincare and beauty consumption.
L'Oreal has observed a notable influence of weight loss drugs on its beauty and skincare sales, prompting product development tailored to mitigate specific side effects. Nicolas Hieronimus, the company's head, stated that the phenomenon of GLP-1 drugs is significant for L'Oreal.
He elaborated that the increasing use of these medications is demonstrably affecting beauty and skincare consumption. L'Oreal announced a 7.7% sales increase in the quarter ending September, surpassing analyst predictions despite a challenging global economic climate.
The boom in GLP-1 drugs, initially developed for diabetes but found to suppress appetite, has led to rapid weight loss for many users. This can result in side effects like loose skin, particularly noticeable around the face.
L'Oreal's brands, including SkinCeuticals and Kiehl's, now offer products designed to complement GLP-1 treatments and address issues such as skin sagging. The company has also strengthened its presence in clinical aesthetics by increasing its stake in dermatology firm Galderma.
Both L'Oreal and Galderma have been conducting clinical trials on GLP-1 users concerned about skin laxity. Galderma's portfolio includes aesthetic products like Sculptra and Restylane, and the firm previously released a report indicating that a majority of weight loss medication users noted changes in their facial appearance.
